Rimcure 3-FDC150 mg+75 mg+400 mg

Rimcure 3-FDC is a fixed-dose combination (FDC) of three first-line antitubercular drugs used in the treatment of tuberculosis (TB).

Established / Guideline-Supported Uses

• Active pulmonary tuberculosis - as part of the intensive (initial) phase of standard first-line short-course anti-TB chemotherapy, usually together with ethambutol, per WHO/CDC and national TB programme guidance, typically for the first 2 months of treatment.
• Active extrapulmonary tuberculosis (e.g., lymph node, pleural, and other forms), used as part of a complete first-line regimen under specialist guidance.

Important Notes on Use

• Rimcure 3-FDC must always be used as part of a complete, physician-directed multi-drug anti-TB regimen (never as a stand-alone treatment), typically combined with a fourth drug (ethambutol), and given under Directly Observed Therapy (DOT) where available, to reduce the risk of treatment failure and drug-resistant TB.
• After the intensive phase, treatment is usually continued with a two-drug regimen (rifampicin + isoniazid) for a further 4 months as part of the standard 6-month course; see Duration of Treatment.
• Use in drug-resistant TB, latent TB infection, or non-tuberculous mycobacterial disease is not supported and is outside the approved use of this combination.

Rifampicin + Isoniazid + Pyrazinamide is available as an oral fixed-dose combination tablet. Common adult strengths (consistent with WHO-prequalified and internationally approved formulations) include:

• Rifampicin 120 mg + Isoniazid 50 mg + Pyrazinamide 300 mg per tablet, or
• Rifampicin 150 mg + Isoniazid 75 mg + Pyrazinamide 400 mg per tablet, depending on the manufacturer/market.

Pediatric dispersible fixed-dose combination tablets (e.g., Rifampicin 75 mg + Isoniazid 50 mg + Pyrazinamide 150 mg) are also available for weight-band dosing in children. Exact strength and excipients vary by brand/manufacturer; always check the specific product label dispensed.

Rimcure 3-FDC is a fixed-dose combination antitubercular medicine that brings together three first-line drugs used in the intensive phase of tuberculosis treatment. Combining these agents into a single tablet simplifies dosing, improves adherence, and reduces the risk of a patient inadvertently taking only one drug, which could otherwise promote drug-resistant TB.

It is prescribed by physicians experienced in TB management, generally as part of national or WHO-recommended TB treatment protocols, and is not intended for self-directed use.

Rimcure 3-FDC belongs to the therapeutic class of first-line antitubercular (anti-TB) fixed-dose combination agents.

Rifampicin + Isoniazid + Pyrazinamide combines three antitubercular drugs with complementary, distinct mechanisms of action:

• Rifampicin inhibits bacterial DNA-dependent RNA polymerase, blocking RNA synthesis and killing both rapidly dividing and slowly metabolizing (persister) Mycobacterium tuberculosis organisms.
• Isoniazid inhibits synthesis of mycolic acids, essential components of the mycobacterial cell wall, and is highly active against rapidly dividing bacilli.
• Pyrazinamide is converted to its active form, pyrazinoic acid, by mycobacterial pyrazinamidase, and is particularly active against semi-dormant bacilli residing in the acidic environment of caseous lesions and within macrophages.

Together, this three-drug action during the intensive phase rapidly reduces bacillary load, shortens infectiousness, and lowers the risk of selecting drug-resistant mutants.

Pharmacokinetics (brief)

All three components are well absorbed orally (absorption of rifampicin is reduced by food), undergo hepatic metabolism, and are eliminated mainly via the liver (rifampicin, with enterohepatic recirculation) and kidney (isoniazid and pyrazinamide metabolites). Isoniazid metabolism (acetylation) is genetically variable ("fast" vs "slow" acetylators), which can affect drug levels and toxicity risk.

Rimcure 3-FDC should be taken:

• Once daily, at the same time each day, preferably on an empty stomach (at least 30 minutes to 1 hour before food), as food can reduce absorption of rifampicin.
• Swallowed whole with a full glass of water; dispersible pediatric tablets may be dissolved in a small amount of water as directed.
• Exactly as prescribed, for the full duration of the intensive phase, ideally under Directly Observed Therapy (DOT).
• Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice - incomplete or irregular treatment risks relapse and drug-resistant tuberculosis.

Rimcure 3-FDC has several clinically significant drug interactions, mainly due to rifampicin's potent induction of hepatic cytochrome P450 enzymes (including CYP3A4) and isoniazid's enzyme-inhibiting effects:

Inform your physician of all prescription, over-the-counter, and herbal products you are taking before and during treatment with Rimcure 3-FDC.

Common and serious adverse effects reported with Rimcure 3-FDC include:

Common

• Gastrointestinal upset (nausea, vomiting, loss of appetite, abdominal discomfort)
• Orange-red discoloration of urine, tears, sweat, and saliva (harmless, expected with rifampicin - may permanently stain soft contact lenses)
• Headache, dizziness

Less Common but Important

• Hepatotoxicity - elevated liver enzymes, jaundice (see Precautions and Warnings)
• Peripheral neuropathy (tingling/numbness in hands and feet), mainly from isoniazid
• Hyperuricemia and arthralgia/joint pain (from pyrazinamide)
• Skin rash, pruritus
• Flu-like syndrome (fever, chills, myalgia) with rifampicin, especially with intermittent dosing

Rare but Serious

• Severe hepatitis/hepatic failure
• Severe hypersensitivity reactions (Stevens-Johnson syndrome, thrombocytopenia, hemolytic anemia, acute kidney injury) - rare

Seek prompt medical attention for yellowing of the eyes/skin, dark urine, unexplained fatigue, persistent vomiting, or signs of severe skin reaction.

Rimcure 3-FDC should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; treatment decisions must be made by a physician experienced in TB management.

Active tuberculosis in pregnancy poses a substantial risk to both mother and fetus if untreated, so standard first-line anti-TB treatment (including this combination) is generally continued during pregnancy under specialist supervision, per WHO/CDC guidance; pyridoxine (vitamin B6) supplementation is recommended to reduce the risk of isoniazid-associated peripheral neuropathy in the mother and infant.

All three components pass into breast milk in small amounts; breastfeeding is generally considered compatible with maternal treatment, but the nursing infant should be monitored, and the decision should be made in consultation with a physician. Pyridoxine supplementation is also recommended for breastfed infants of mothers on isoniazid-containing regimens.

Hepatotoxicity: This is the most significant risk associated with Rimcure 3-FDC. Baseline liver function tests are recommended before starting treatment, with periodic monitoring during treatment, especially in patients with pre-existing liver disease, heavy alcohol use, or those on other hepatotoxic drugs. Seek immediate medical attention for jaundice (yellowing of eyes/skin), dark urine, unexplained nausea/vomiting, loss of appetite, or unusual fatigue - these may indicate drug-induced liver injury requiring treatment interruption.

Peripheral neuropathy: Isoniazid can cause peripheral neuropathy, particularly in patients who are malnourished, diabetic, have chronic kidney disease, HIV infection, alcohol dependence, or are pregnant/breastfeeding. Co-administration of pyridoxine (vitamin B6) is recommended in at-risk patients to reduce this risk.

Body fluid discoloration: Rifampicin causes a harmless orange-red discoloration of urine, tears, sweat, and saliva; patients should be counseled about this expected effect and warned that soft contact lenses may be permanently stained.

Hyperuricemia/gout: Pyrazinamide can raise uric acid levels and precipitate gout; use with caution in patients with a history of gout or hyperuricemia (contraindicated in acute gout).

Drug interactions: Rifampicin is a potent inducer of hepatic enzymes; review all concurrent medications, particularly hormonal contraceptives, anticoagulants, and antiretrovirals (see Interactions).

Antitubercular stewardship: Take exactly as prescribed by your physician; do not stop, extend, skip doses, or share this medicine with others without medical advice - incomplete or irregular treatment risks relapse and multidrug-resistant tuberculosis.

Overdose with Rimcure 3-FDC is a medical emergency. Symptoms may include nausea, vomiting, abdominal pain, liver enlargement, jaundice, seizures (particularly from isoniazid overdose, which can cause refractory seizures and severe metabolic acidosis), altered consciousness, and cardiac/respiratory compromise in severe cases.

If overdose is suspected, seek immediate medical attention or contact the nearest emergency department/poison control center right away. Do not attempt to manage a suspected overdose at home; specific treatment (e.g., pyridoxine for isoniazid-induced seizures) may be required and should only be given under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

Rifampicin and isoniazid are primarily eliminated hepatically and generally do not require dose adjustment in renal impairment; pyrazinamide metabolites accumulate in significant renal impairment, so dosing frequency may need adjustment - specialist guidance is advised.

Hepatic Impairment

Use with caution and close monitoring in patients with pre-existing liver disease; contraindicated in severe active liver disease (see Contraindications).

Elderly

Older adults may be at higher risk of hepatotoxicity; use with close clinical and laboratory monitoring.

HIV Co-infection

Requires careful coordination with antiretroviral therapy because of significant interactions with rifampicin; managed by physicians experienced in TB/HIV co-treatment.

Diabetes / Malnutrition / Alcohol Use

Higher risk of isoniazid-associated peripheral neuropathy; pyridoxine supplementation recommended.

Rimcure 3-FDC is used during the intensive (initial) phase of standard first-line TB treatment, typically for 2 months, usually together with ethambutol.

This is generally followed by a continuation phase of 4 months with a two-drug combination (rifampicin + isoniazid only, without pyrazinamide), making a standard total treatment course of about 6 months for most drug-susceptible pulmonary TB.

Longer courses (e.g., 9-12 months) may be required for certain forms of extrapulmonary TB (such as TB meningitis or bone/joint TB) or in specific clinical situations, as determined by the treating physician/national TB programme. Treatment duration and phase transitions must always be decided by the prescribing physician - never self-adjust the duration.

Antitubercular agents - fixed-dose combination of a rifamycin (rifampicin), an isonicotinic acid hydrazide derivative (isoniazid), and a pyrazinoic acid amide (pyrazinamide).

Rifampicin blocks bacterial RNA polymerase, halting RNA synthesis; isoniazid blocks mycolic acid synthesis, disrupting the mycobacterial cell wall; pyrazinamide is converted to active pyrazinoic acid, which disrupts membrane function and is especially effective in the acidic, semi-dormant intracellular environment. The combined, complementary bactericidal action across different bacterial subpopulations underlies the effectiveness of the intensive-phase anti-TB regimen.

C

Pediatric-strength dispersible fixed-dose combination tablets of Rimcure 3-FDC are used in children with active TB, dosed by weight-band according to WHO-recommended pediatric dosing charts, generally during the 2-month intensive phase alongside ethambutol, under physician/TB programme supervision.

Safety and efficacy in neonates and very low birth weight infants have not been well established; treatment decisions in this age group should be individualized by a pediatric TB specialist. Pyridoxine supplementation is recommended for children at higher risk of isoniazid-associated neuropathy (e.g., malnourished children, those with HIV).